NCT03073213View on ClinicalTrials.gov

A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 13, 2017

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
Psoriasis
Interventions
DRUG

Ixekizumab

Administered as subcutaneous (SC) injection

Trial Locations (3)

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai

310009

Second Affiliate Hospital of Zhejiang Medical University, Hangzhou

Unknown

Xiangya Hospital, Central South University, Changsha

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03073213 - A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris | Biotech Hunter | Biotech Hunter